The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Latest Information Update: 11 May 2023
At a glance
- Drugs CORVAX12 (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TRIFECTA
- 01 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2022 Planned number of patients changed from 68 to 96.